Group items matching

in title, tags, annotations or url

Dr. Reddy's Teraleve® 4mg and 8mg Fesoterodine Fumarate Prolonged-Release tablets have been available in the UK since their launch on 1st June 2022. Therapeutic indications: Indicated in adults for treatment of the symptoms (increased urinary frequency and/or urgency and/or urgency incontinence) that may occur with overactive bladder syndrome. Presentation: 4mg tablets are light blue, oval, biconvex, film-coated, and engraved on one side with the number '4'. 8mg tablets are light blue, oval, biconvex, film-coated, and engraved on one side with the number '8'. Tablets are packaged in aluminium-aluminium blisters in a carton with a PIL.

he Pharmacy Schools Council (PhSC) has elected Professor Katie Maddock as the organisation's new chair. Prior to becoming head of school at Keele University, Professor Maddock had been MPharm course director and associate dean for education for the Faculty of Medicine and Health Sciences, responsible for developing the clinical teaching at Keele. Before joining Keele University, she taught clinical pharmacy and pharmacy practice at Aston University. Her research interests lie in pharmacy education, particularly the use of technology in teaching, clinical therapeutics, augmented reality simulation and interprofessional education. She was also awarded a principal fellowship of the Higher Education Academy in November 2020. Having worked in hospital pharmacy, Professor Maddock is acutely aware of the pressures that Covid-19 has placed on healthcare, as well as the importance of retaining and building upon the positive changes to patient care and pharmacy practice that were developed in response to the pandemic.

The Scottish Medicines Consortium (SMC) has accepted AbbVie's RINVOQ (upadacitinib) for use within NHS Scotland for the treatment of adult patients with moderately to severely active ulcerative colitis (UC). Upadacitinib offers an additional treatment choice in the therapeutic class of janus kinase inhibitors. "Daily life with ulcerative colitis is difficult due to the debilitating and unpredictable nature of its symptoms", said Dr Jonathan Macdonald, Consultant Gastroenterologist at NHS Greater Glasgow and Clyde. "Clinical trials have shown that upadacitinib as a once daily pill controls symptoms in eight weeks for many patients and provided sustained responses at one year. The SMC's decision is good news for people with ulcerative colitis in Scotland as it provides an additional treatment option to help them gain control of their condition." The SMC decision is based on data from the induction studies U-ACHIEVE and U-ACCOMPLISH, as well as the Phase 3 U-ACHIEVE maintenance study, which demonstrated the efficacy of upadacitinib versus placebo in its ability to achieve clinical remission. The SMC's decision follows the granting of Marketing Authorisation for upadacitinib in UC in July 2022.

Rosemont Pharmaceuticals (Rosemont) has acquired Lucis Pharma Ltd, a specialist pharmaceutical business in the UK. Through this acquisition Rosemont will expand its existing portfolio and have access to a pipeline of innovative products, providing lifesaving pharmaceuticals to the UK and overseas markets. Founded in 2012, Lucis has grown to become a leading provider in the development and licensing of novel and exclusive medicines. With over a dozen SKUs covering a variety of therapeutic areas, Lucis has established a strong portfolio that, in addition to a pipeline of innovative developments, serve the growing patient need for liquid medicines. The acquisition will enable Rosemont to broaden its portfolio and enter the unit dose / sachet market through the pipeline products, whilst growing the business through recent Lucis product launches in 2021/22. "As well as continuing to broaden our portfolio and add to our strong growth globally, this acquisition also gives access to pipeline products and developer relationships to accelerate our entry into new product areas such as sachets" said Howard Taylor, Chief Executive Officer of Rosemont.

Denmark's Zealand Pharma and Boehringer Ingelheim said their experimental obesity treatment achieved up to 14.9% weight loss in a mid-stage trial, lining up a potential contestant in the booming obesity drug market. In a statement on Wednesday (May 10), the partners said that the Phase II dose-finding trial met its primary endpoint of weight loss after 46 weeks. Paola Casarosa, head of therapeutic areas at Germany's Boehringer Ingelheim told Reuters the partners are in discussion with regulators about the design of a planned follow-up trial in the third and last phase of testing. The enormous demand for weight-loss treatments such as Novo Nordisk's Wegovy, or potentially Eli Lilly's Mounjaro, could support as many as 10 competing products with annual sales reaching up to $100 billion within a decade, mostly in the United States, industry executives and analysts said. Lilly said about a year ago that Mounjaro was shown to reduce up to 22.5% in weight after 72 weeks of treatment in a much larger late-stage trial.

Royal Pharmaceutical Society (RPS) and the Royal College of General Practitioners in Scotland hosted an event celebrating the collaborative work of the health professions and policy makers in Scotland on reducing the environmental harm from prescribing and medicines use. To share priorities for the Scottish Government, Alpana Mair, Head of Effective Therapeutics and Prescribing spoke and National Clinical Director Jason Leitch appeared virtually. Gillian MacKay MSP, Scottish Greens spokesperson for Health and Social Care also joined in-person. Medicines account for around 25% of the NHS's carbon emissions and have an ecological impact when they enter our wastewater system or our rivers and oceans. Tackling the impact of prescribing will be a key part of meeting the ambition of a net zero NHS Scotland by 2040 at the latest. Together, RCGP Scotland and RPS have held two roundtable events on sustainable prescribing, and in June 2022, released a joint statement calling for a wide range of actions, which was signed by the Academy of Medical Royal Colleges and Faculties in Scotland, the Royal College of Physicians of Edinburgh, the Royal College of Anaesthetists, the College of Radiographers, Royal College of Nursing, Queen's Nursing Institute Scotland and Chartered Society of Physiotherapy. Continuing the work of RPS at the International Forum on Quality and Safety in Healthcare, the event aims to mark an opportunity for health professionals and decision makers alike to join a global movement of sustainability in healthcare, and pledge to continue the important work of cutting the climate impact of medicine use while maintaining the highest level of patient care and safety.

The British scientists behind one of the major therapeutic Covid-19 trials have turned their focus to treatments for monkeypox, a viral disease that has been labelled a global health emergency by the World Health Organization. The team from Oxford University behind the so-called RECOVERY trial - which honed in on four effective Covid treatments - on Tuesday unveiled a new trial, dubbed PLATINUM, to confirm whether Siga Technologies' tecovirimat is an effective treatment for monkeypox. Although there are vaccines developed for the closely related smallpox that can reduce the risk of catching monkeypox, there are currently no treatments that have been proven to help hasten recovery in those who develop the disease. The UK has over 3,000 confirmed cases of monkeypox. The virus is transmitted chiefly through close contact with an infected person. It typically causes mild symptoms including fever, rash, swollen lymph nodes and pus-filled skin lesions. Severe cases can occur, though people tend to recover within two to four weeks. Siga's drug, branded Tpoxx, has been cleared to treat diseases caused by the family of orthopoxvirus that includes smallpox, monkeypox and cowpox by the European Union and United Kingdom, but due to limited trial data it is generally only used in severe cases in Britain.

Pfizer said on Tuesday it will pay $11.6 billion to buy Biohaven Pharmaceuticals, making a big bet on its ability to boost sales of the top-selling pill in a new class of migraine drugs. The boards of both companies have approved the deal, they said. Biohaven shares jumped 70 per cent to $141.31, while Pfizer was up slightly at $48.83. Pfizer is flush with cash from a once-in-a-lifetime surge in revenue from Covid-19 vaccines and therapeutics and has said it is looking to buy companies or drugs that could add at least $25 billion in annual sales by the end of the decade. "The CGRP oral medications, though still somewhat newer entrants in a deeply entrenched space, continue to make steady inroads in disrupting the broader migraine market in the U.S.," said BioHaven chief executive Vlad Coric. Biohaven forecast Nurtec sales of $825 million to $900 million in 2022. Pfizer said it expects the pills to eventually overtake the shots.

Pharmacists with 'relevant experience in a pharmacy setting' can enroll for accredited independent prescribing course, as the General Pharmaceutical Council (GPhC) has decided to scrap the requirement of spending at least two years on the register and having previous experience in a specified clinical or therapeutic area before enrolling for the course. The GPhC Council meeting held on Thursday instead proposed that applicants must have "relevant experience in a pharmacy setting and be able to recognise, understand and articulate the skills and attributes required by a prescriber." This experience and awareness will act as the basis of their prescribing practice whilst training. The regulator noted that the majority of stakeholder organisations, including the Chief Pharmaceutical Officers, the Royal Pharmaceutical Society and the statutory education bodies, were in favour of removing the requirement in a consultation on the topic. They highlighted that a specific two-year period was not in itself a robust indication of whether an individual was ready to become a prescriber. They also highlighted that the rapidly developing roles in the profession meant more pharmacists were likely to gain the necessary experience more quickly than in the past. A smaller number of organisations and a larger minority of individuals were opposed, citing that a specific two-year period gave pharmacists the time they needed to develop experience and confidence before being ready to enrol on a course.

Ginger is a robust equatorial vegetable with a wealth of health benefits and is surprisingly easy to grow at home. At the same time, its therapeutic features are known to improve the immune system and ease digestive problems. Often seen in Indian and Asian cuisine, ginger fosters a flavorful zest to dishes. You can consume the roots of this underground plant fresh, powdered, dried, in oil, or added to a juice or smoothie. Being a tropical vegetable, it will not be able to endure frosty weather. The best time to start growing ginger for home is the early springtime, after the last of the frost. If you live in the tropics, at the beginning of the wet season. Knowing how growing ginger is worth it if you want condiments and spices for your kitchen.

As the weather gets colder, we're all looking for ways to get through the winter months. One of the most popular natural remedies is ginger. It's been used for thousands of years and has been shown to relieve symptoms like sore throat and coughing as well as boost overall health. People often use ginger as a home remedy for treating colds and sore throats due to its antibacterial markers that can help handle pain and inflammation. The Ginger (Zingiber officinale) root is a perennial plant. Our forefathers have consumed ginger as a herbal therapy for decades after decades to cure many health conditions, from arthritis to abdominal pain. Today, we often use ginger when we have a cough or cold. The scientific database reveals that ginger has medicinal effects that could ease the symptoms of a cold or sore throat. This article will examine how ginger may help colds and how you can use it in teas, juices, and other home remedies. How is ginger good for treating Colds? There is no definitive proof that ginger can cure or eliminate colds from roots, but research indicates that it may help control them. Ginger can also aid in improving cold symptoms. One study review shows that there is evidence that ginger can help: prevent colds control or relieve a sore throat ease congestion decrease inflammation However, researchers need to examine ginger's additional benefits to support this evidence. Medicinal properties Ginger has blends called gingerols and shogaols. Experimenters consider that these compounds give ginger its therapeutic properties. It is a potent anti-inflammatory. It's also a natural expectorant and decongestant, which helps to clear up congestion. Ginger is high in vitamin C and manganese, both essential nutrients for boosting your immune system during the cold season. While ginger may not be a cure-all for the common cold or flu (it's always best to consult your doctor if you're sick), it can help keep you feeling better while you recover. Stu

Dark spots or hyperpigmentation might force you to pick skin-bleaching products to even skin tone, but their results can be the least, and the odds are doubled. Applying sunscreen daily and articulate with a dermatologist is the easiest way to protect your skin from dark spots. But if you want to pick a natural alternative for dark spots or hyperpigmentation, what could be a better natural alternative than spice turmeric? Yes, TURMERIC SOAP FOR DARK SPOTS. You may wonder why turmeric retard the melanin production in your skin cells because melanin is the pigment that forms dark spots and other types of hyperpigmentation. Using turmeric-oriented products or turmeric soap benefits uneven skin naturally. After three to eight weeks, you'll see that turmeric soap is fading the dark spots and giving your skin a more even-toned impression! Hyperpigmentation, or dark spots, can be induced by acne scars, extreme sun openness, or hormonal shifts, according to Dr. Asim Sohail, Dermatologist, Cosmetologist, M.B.B.S., M.C.P.S. (Dermatology), A.A.C.M.E. (U.S.A.), Professional Diploma in facial aesthetics. The market is full of various creams and serums that patients often utilize to help fade, brighten, and even dark spots over time," he said. Each of these therapeutic choices may put you at risk. Read on to uncover which alternative may work best in your case. Turmeric Soap For Dark Spots: A 2018 Journal of Clinical and Aesthetic Dermatology review found that natural ingredients effectively manage dark spots or hyperpigmentation. Among these natural ingredients, turmeric was proven to reduce the appearance of dark spots within four weeks of usage. However, due to the shortage of clinical studies on the issue, turmeric's skin-lightening benefits have yet to be resolved. READ MORE * * * * * * * * https://amvital.com/turmeric-soap-for-dark-spots-know-the-truth/?v=1d20b5ff1ee9

The UK Health Security Agency (UKHSA) and The Pirbright Institute have launched a new collaboration to develop vaccines against henipavirus, a genus of viruses that includes Nipah virus. Funded by the Medical Research Council, this research aims to develop a vaccine that provides cross protection against the whole genus, addressing the threat of outbreaks from new or emerging henipaviruses and strengthening epidemic preparedness. Scientists at UKHSA will evaluate the protective efficacy of vaccines developed by The Pirbright Institute by using use a model of Nipah virus disease, which mimics the infection in humans. Professor Isabel Oliver, chief scientific officer at UKHSA, stated that the study would improve understanding of henipaviruses and enhance efforts to protect health from this "current and future global health threat." "The work will also make a vital contribution to the 100 Days Mission - an important initiative to make sure the world is better prepared for the next pandemic by accelerating the development of diagnostics, therapeutics and vaccines," he added.

Cancer patients in the UK are being given a new immunotherapy treatment at Imperial College Healthcare NHS Trust as part of a global phase 1/2 clinical trial, which aims to evaluate its safety and potential for treating 'solid tumour' cancers such as melanoma and lung cancer. The experimental therapy, called mRNA-4359, has been designed to train patients' immune systems to recognise and fight cancer cells, according to researchers at Imperial College London. For the first time in the UK, cancer patients received the treatment at the National Institute for Health and Care Research (NIHR) Imperial Clinical Research Facility at Hammersmith Hospital. In this non-randomised trial, mRNA-4359 is administered to patients either alone or in combination with an existing cancer drug called pembrolizumab, a type of immune checkpoint inhibitor. The researchers are hopeful that this new therapeutic approach, if proven to be safe and effective in clinical trials, could lead to a new treatment option for difficult-to-treat cancers.

Recent NHS data sheds light on the evolving landscape of fit note certification, indicating a gradual expansion of roles beyond traditional medical practitioners to pharmacists and nurses. This uptake in numbers coincides with the Department of Work and Pensions's (DWP) call for evidence in relation to fit note reform which will remain open till 8 July 2024. According to figures published by NHS Digital, during the nine-month period from April 2023 to December 2023, pharmacists certified a significant number of fit notes. Approximately 1.4 per cent of fit notes of the 8 million were issued by pharmacists while the rest were issued by the GP surgeries reflecting the impact following legislative amendments in July 2022, which extended certification authority to pharmacists, nurses, occupational therapists, and physiotherapists. In June 2022, the Pharmacists' Defence Association (PDA) advised pharmacists not to sign fit notes where the required therapeutic, diagnostic, or examination skills lie outside their scope of competence. The association remarked that healthcare professionals needed mandatory training under the Health Education England before they are fit to issue fitness notes to the public.

Aspire Pharma Limited has solidified its position as a leading specialty generics enterprise by adding leuprorelin acetate as a branded generic to its oncology portfolio. Leuprorelin acetate is hormone therapy recommended for patients with high-risk localised, locally advanced, and metastatic prostate cancer, serving as an alternative to surgical castration for locally advanced cases. Used as an alternative to surgical castration for locally advanced prostate cancer, a pre-filled syringe containing 11.25mg of leuprorelin acetate (equivalent to 10.72 mg leuprorelin) is injected subcutaneously into the abdomen. The British pharmaceutical company noted that one of its primary objectives is to seek "new investment opportunities" that brings products and companies into its portfolio, aligning closely with Aspire values and therapeutic focus areas. Prostate cancer is the most common cancer among men in the UK, with an average of over 52,000 men receiving a diagnosis of prostate cancer annually, as per Prostate Cancer UK.

Adding to the growing evidence of global medicine shortages, a new study has revealed that the European generic medicines market is "not in shape" to help Europe meet its public health priorities. In the past decade, the rate of generic medicines withdrawals has risen by 12 per cent, while there has been a three per cent decrease in the launch of generic products, as per Teva Pharmaceuticals' recent analysis of IQVIA data. Within the mental therapeutic area, seven per cent of generic products disappeared between 2013 and 2023, while there was a seven per cent decrease in the availability of generic cancer medicines in just six years (2017-2022). These medicines were listed on the Union List of Critical Medicines to help avoid potential shortages, as the European Commission (EC) said this could cause "significant harm to patients and pose important challenges to health systems." While mature generic products constitute the majority of the List, they remain susceptible to withdrawals, despite containing products crucial for safeguarding Europe's public health, the Teva analysis report noted. Since 2013, the number of generic products for the treatment of schizophrenia and bipolar disorder has declined by 25 per cent, with Hungary and Bulgaria experiencing the biggest loss at 83 per cent and 58 per cent respectively.

Drug delivery to the cardiovascular system is approached at three levels: (1) routes of drug delivery; (2) formulations; and finally (3) applications to various diseases. Formulations for drug delivery to the cardiovascular system range from controlled release preparations to delivery of proteins and peptides. Cell and gene therapies, including antisense and RNA interference, are described in full chapters as they are the most innovative methods of delivery of therapeutics. Various methods of improving systemic administration of drugs for cardiovascular disorders are described including use of nanotechnology.

Hand Drive Tricycle or tricycle For handicapped is product, designed for use with bikes meant for the open road. Instead of shifting with a foot, a rider can drive easily their tricycle on road using his or her hand. This piece of equipment has been tested well. We provides assembly and installation for all of our products at our facilities in Indore. We conduct free consultations for all prospective customers to see how we can fulfill your specific needs.